Full Title: The Pediatric Obesity Microbiome and Metabolism Study (POMMS): Methods, Baseline Data, and Early Insights.

First Author Surname and Short Title: McCann; Adolescent Obesity Study

Word Count: 3980

Authors Names, Academic degrees, affiliations:

Jessica R. McCann, PhD[1] (jessica.mccann@duke.edu)

Nathan A. Bihlmeyer, PhD[2] (nathan.bihlmeyer@duke.edu)

Kimberly Roche[1] (kimberly.roche@duke.edu)

Cameron Catherine[3] (cameroncatherine3@gmail.com)

Jayanth Jawahar[1] (jayanth.jawahar@duke.edu)

Lydia Coulter Kwee, PhD[2] (lydia.kwee@duke.edu)

Noelle E. Younge, MD[3] (noelle.younge@duke.edu)

Justin Silverman (jsilve24@gmail.com)

Olga Ilkayeva, PhD[2] (olga.ilkayeva@duke.edu)

Charles Sarria[1] (charlesjsarria@ufl.edu)

Alexandra Zizzi[1] (alexandra.zizzi@duke.edu)

Janet Wootton[1] (janet.wootton@duke.edu)

Lisa Poppe[2] (lisa.poppe@duke.edu)

Paul Anderson[2] (paul.r.anderson@duke.edu)

Michelle Arlotto[2] (michellee.arlotto@duke.edu)

Zhengzheng Wei, PhD[1] (zhengzheng.wei@duke.edu)

Joshua A. Granek, PhD[1,5] (joshua.granek@duke.edu)

Raphael H. Valdivia, PhD[1,5] (raphael.valdivia@duke.edu)

Lawrence A. David, PhD[1,5] (lawrence.david@duke.edu)

Holly K. Dressman, PhD[1,5] (holly.dressman@duke.edu)

Christopher B. Newgard, PhD[2] (chris.newgard@duke.edu)

Svati H. Shah, MD MHS[2,4] (svati.shah@duke.edu)

Patrick C. Seed, MD PhD[6] * (patrick.seed@northwestern.edu)

John F. Rawls, PhD[1,5] * (john.rawls@duke.edu)

Sarah C. Armstrong, MD[3,4] * (sarah.c.armstrong@duke.edu)

1. Department of Molecular Genetics and Microbiology, Duke University, Durham, NC 27708
2. Duke Molecular Physiology Institute and Sarah W. Stedman Nutrition and Metabolism Center, Duke University, Durham, NC, USA 27710
3. Department of Pediatrics, Duke University, Durham, NC, USA 27710
4. Duke Clinical Research Institute, Duke University, Durham, NC, USA 27710
5. Duke Microbiome Center, Duke University Durham, NC, USA 27710
6. Ann & Robert H. Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine, Stanley Manne Children's Research Institute, Northwestern University Medical Center, Chicago, IL, USA 60611

Name and Complete Address for Correspondence:

*** Corresponding Authors**

CONTRIBUTIONS

PCS, JFR, SHS, and SCA designed and provided supervision for the study, secured funding, wrote and edited original draft. JRM acted as project manager, curated and analyzed data, wrote and

edited original draft. NAB, KR, PCS, JJ, LCK, CBN, JS, and NY curated, analyzed, and interpreted data. SHS, CC, CS, AZ, and JW coordinated clinical activities, collected samples, and curated data. LP, PA, and MA collected samples and curated data. OI, ZW, LAD, and HKD analyzed samples and provided statistical and planning advice. All authors were involved in writing the paper and had final approval of the submitted and published versions.

What is already known about this subject?

- The intestinal microbiome plays an important role in adult obesity and regulation of metabolism. Although it is well-established that obesity has its roots in childhood, very little is known about the role of the microbiome in pediatric obesity and how it changes during adolescence.

What are the new findings in your manuscript?

- This manuscript provides details of a new shared biorepository including clinical data, stool samples and plasma samples from a diverse cohort of 223 adolescents with obesity followed longitudinally over 6 months during a weight management intervention, as well as 71 adolescents with healthy weight as a comparison group.
- Interim analyses suggest that adolescents with obesity have microbiome signatures and metabolite profiles similar to adults, however key differences in microbial communities and metabolic by-products are identified.

How might your results change the direction of research or focus of clinical practice?

- The POMMS biorepository will be available for investigators to use in future research, to elucidate the underlying mechanisms of obesity and related chronic health conditions.
- Preliminary data reveal metabolite profiles that suggest adolescence may be a window of metabolic plasticity and disease reversibility

- Microbiome and metabolomic signatures suggest potential biomarkers that may serve as prognostic or predictive factors in disease remission, or targets for future therapeutics.

ABSTRACT

Objective: To establish a biorepository of clinical, metabolomic, and microbiome samples from adolescents with obesity as they undergo lifestyle modification.

Methods: We enrolled 223 adolescents aged 10-18 years with Body Mass Index ≥ 95th percentile, along with 71 healthy weight participants. We collected clinical data, fasting serum, and fecal samples at repeated intervals over 6 months. Here we present our study design, data collection methods, and an interim analysis, including targeted serum metabolite measurements and fecal 16S rRNA gene amplicon sequencing among adolescents with obesity (n=27) and healthy weight controls (n=27).

Results: Adolescents with obesity have higher serum alanine aminotransferase, C-reactive protein, and glycated hemoglobin, and lower high-density lipoprotein cholesterol when compared with healthy weight controls. Metabolomics revealed differences in branched chain amino acid related metabolites. We also observed differential abundance of specific microbial taxa and lower species diversity among adolescents with obesity when compared with the healthy weight group.

Conclusions: The Duke Pediatric Metabolism and Microbiome Study biorepository is available as a shared resource. Early findings suggest evidence of a metabolic signature of obesity unique to adolescents, along with confirmation of previously reported findings describing metabolic and microbiome markers of obesity.

Clinical Trial Registration:

Biorepository: NCT02959034

Observational Trial: NCT03139877

Keywords

Pediatric, obesity, adolescents, microbiome, metabolism

INTRODUCTION

Despite sustained research into effective treatment strategies, pediatric obesity remains at epidemic levels, and strongly predicts adult obesity, metabolic, and cardiovascular disease (1). Currently, one in three children in the US are classified as overweight or obese, with the highest prevalence among low-income and non-white youth (2). The US Preventative Service Task Force recommends that pediatric providers screen all children aged 6-18 years for obesity annually, using the Centers for Disease Control and Prevention sex- and age-specific Body Mass Index (BMI) curves. Additionally, children with BMI at or above the 95th percentile should be referred to a comprehensive behavioral intervention of medium to high intensity, defined as achieving ≥26 hours of contact over six months (3). However, existing data show that recommended interventions for pediatric obesity result in a heterogeneous response, with most participants showing non-significant BMI reduction (4), with little understanding of the underlying predictive factors for treatment success.

Strong evidence suggests that the intestinal microbiome and its products influence chronic diseases such as obesity, insulin resistance, and heart disease (5). Observational studies in adult humans and stool transplantation experiments in animal models have found

novel connections among obesity, insulin resistance, metabolic pathways, inflammation, and intestinal microbiota that may differ between individuals (6). Circulating and tissue metabolites serve as diagnostic, prognostic, and therapeutic targets for metabolic disease, and can be affected by microbiome composition (7). Thus, analyses of the microbiome and metabolome have the potential to provide insights into the host-microbiome pathways and inform personalized and effective treatments.

Adolescents provide a unique opportunity to garner deeper insights into the obesity-associated microbiome and related metabolic pathways during the transition from childhood to adulthood. First, adolescents with severe obesity mimic adult metabolic and cardiovascular risk phenotypes (8, 9). However, unlike adults, adolescents are at early stages of disease, have fewer and less severe co-morbid conditions, and tend to be treatment-naïve. Second, adolescence is a unique window of development and its associated microbiome and metabolic signatures in health and disease are understudied compared to those signatures in adults (10). Similarly, while significant evidence supports the association between decreased gut microbiome diversity and obesity in adults, this has not been confirmed in a larger and racially diverse group of adolescents (11). Third, the prospective longitudinal design of adolescents enrolled in weight mangagment will provide insights into metabolomic and microbiome changes in response to treatment and the early biomarkers of improved health. Last, while obesity and its complications are more prevalent in racial and ethnic minorities, most studies to date have not enrolled significant numbers of these groups, limiting our ability to treat the most at-risk populations (12).

The Pediatric Obesity Microbiome and Metabolism Study (POMMS) is an NIH-funded prospective observational study with two main objectives: 1) to identify serum

metabolic biomarkers or stool microbial signatures in adolescents for obesity severity, obesity-related comorbid disease, and the later development of obesity-related disease; and 2) to identify serum or stool biomarkers that predict response to treatment, precede response to treatment, or that may help to personalize treatment to optimize individual outcomes. We describe herein the POMMS methods and procedures, as well as early findings from an interim analysis of 27 participants with obesity and 27 healthy weight controls.

METHODS

Screening and enrollment

Research coordinators screened patients referred by their primary care physician to the Duke Healthy Lifestyles clinic in Durham, NC for obesity treatment. Study inclusion criteria were age 10-18 years, Sexual Maturity Rating ≥ 2, age- and gender- specific BMI ≥ 95th percentile, ability to communicate in English or Spanish, and plans to stay in weight management for ≥ 6 months. Patients were excluded for recent weight loss of ≥ 5%, antibiotic use in the prior month or anticipated in the next 6 months, immunodeficiency, prior transplantation, Type 1 diabetes mellitus, inborn errors of metabolism, endogenous obesity (i.e. hyperthyroidism, Cushing syndrome, Mc4R mutation), drug-induced obesity (steroids or anti-psychotics), a significant medical or mental health condition, or pregnancy. Healthy weight controls were recruited from the same community health system, aged 10-18 years with a Sexual Maturity Rating ≥ 2, and age- and gender-specific BMI ≥5th and <85th percentile.

Study design

The study design and procedures were approved by the Duke Institutional Review Board. Eligible participants had parental consent and child assent for the observational study and long-term storage and future use of clinical data and biospecimens. Figure 1 highlights the prospective observational treatment group assignment and study assessments.

Groups

All participants in the intervention (obese or OB) group are patients in the Healthy Lifestyles program, which includes visits to a multi-disciplinary clinic and membership in a community-based fitness program (described below and in Supplemental Methods). All participants in the comparison (healthy weight or HWC) group received a single measurement at baseline only and no additional intervention.

The Healthy Lifestyles clinic is a tertiary-care weight management program that meets current recommendations for family-based child and adolescent obesity treatment (13). The Healthy Lifestyles clinic sees 800 new patients aged 2-18 annually, and more than 15,000 children have received care to date with demonstrated efficacy (14). Advanced treatment options include a low-carbohydrate diet (<30g carbohydrate/day), weight-loss medications (e.g. metformin, phentermine, lisdexamphetamine, lorcaserin, and topriamate), and surgery (Roux-en-Y Gastric Bypass or Laparascopic Vertical Sleeve Gastrectomy). Shared decision-making between parent, teen, and healthcare provider guides treatment choice, and decisions are made based on child's age, obesity severity, comorbidities, and family preference. In addition to clinical care, participants are enrolled in

a community-based fitness program, delivered through a local Parks and Recreation Department (see Supplemental Methods for details).

Measures

The primary study outcome was change in BMI at 3 and 6 months and was determined through standardized measures of body weight and height measured at baseline, 3 and 6 months using a digital scale and stadiometer . A large number of children referred to the Healthy Lifestyles clinic have a BMI significantly greater than the 95th percentile. Therefore, as recommended by Flegal *et al*. (15) we assess and report raw BMI, BMI percentile, and child relative BMI, expressed as a standard deviation score (zBMI) and as a percent of the BMI value at the 95th percentile (%95th BMI) to evaluate and track obesity.

Secondary endpoints were collected at baseline, 3 and 6 months. Cardiorespiratory fitness was assessed by heart rate at the completion of the YMCA submaximal bench-stepping test (16). Blood pressure was measured with a calibrated auscultatory sphygmomanometer in the seated position with an appropriately sized cuff using standard methods (17). Fasting blood samples were obtained for measuring cardiometabolic biomarkers, including lipids, glucose, and transaminases as described in Supplemental Methods. Body fat percentage was measured using calibrated bioelectrical impedance. Parent BMI was directly measured from parent height and weight using calibrated stadiometers.

Survey data (available in English and Spanish) included weight-specific quality of life, measured using the validated “Sizing Me Up” child obesity-specific instrument at

baseline and 6 months (18). Household income, transportation access, parent stress, food insecurity, home food environment, and parental expectations for treatment were also collected at baseline (Supplemental Methods). Factors likely to influence the intestinal microbiome, including birthweight, breastfeeding history, pets in the home, recent or distant antibiotic use, concurrent medication use, and other self-reported measures were recorded.

Serum: Following a fast of 8-14 hours, blood was collected in anti-coagulant containing tiger top (Becton Dickenson (BD) #367988) and green top (BD #367874) tubes at baseline, 3 and 6 months. Blood samples were processed within 2 hours of collection according to established protocols (19). Serum samples were then snap frozen in liquid nitrogen and stored at -80°C in the Duke Children's Biobank.

Stool: Patients collected stool samples and immediately stored the collection container (Fisher Scientific #02-544-208) in their home freezer. Patients then returned the sample or scheduled a home pickup within 18 hours of stooling. Stool was transported frozen and transferred to a -80°C freezer for long-term storage. Stool samples for analysis were processed by thawing on ice in a biological safety cabinet, and opened to the atmosphere for a maximum of 10 minutes while samples were portioned into approximately 2g aliquots. Aliquots were then stored at -80ºC in the Duke Children's Biobank.

Serum and stool samples were organized into a POMMS Biorepository that is available for researchers, with complete clinical data, and fecal and serum longitudinal sample sets from 50 HWC and 140 OB and baseline data and samples from over 200 adolescents with obesity. More information on the repository, sample requests, protocols, recruitment and study completion incentivizing strategies can be found at https://sites.duke.edu/pomms/.

Interim analysis

An interim group of baseline samples in the POMMS Biorepository was selected for an initial analysis of association between metabolites and microbiome characteristics and adolescent obesity. These interim analysis samples were taken at the study enrollment visit from early study entrants and included 27 healthy weight controls (HWC) and 27 adolescents with obesity (OB) matched for puberty status, sex, and ethnicity.

Targeted serum metabolite analysis

Sample preparation and data acquisition: 74 amino acids, acylcarnitines and organic acids were analyzed by targeted mass spectrometry methods employing stable isotope dilution for analyte quantitation. Amino acids and acylcarnitine were measured by flow injection tandem mass spectrometry using sample preparation methods described previously (20). The data were acquired using a Waters TQD mass spectrometer equipped with AcquityTM UPLC system and controlled by MassLynx 4.1 operating system (Waters, Milford, MA). Organic acids were quantified as described (21), employing Trace Ultra GC coupled to ISQ MS operating under Xcalibur 2.2 (Thermo Fisher Scientific, Austin, TX).

Statistical analysis: Levels of all targeted metabolites were log-transformed and tested for association with obesity using a linear model, adjusting for baseline BMI, age, sex, race, and ethnicity and correcting for false discovery rate (22). The complete set of metabolite data can be found online (Supplemental Data Table 1).

16S rRNA gene sequencing

DNA purification, amplification, and sequencing: The Duke Microbiome Shared Resource staff extracted bacterial DNA from stool sample aliquots (~120 mg stool per sample) using a MagAttract PowerSoil DNA EP Kit (Qiagen, 27100-4-EP) and a Retsch

MM400 plate shaker. Resulting DNA concentration was assessed using a Qubit dsDNA HS assay kit (ThermoFisher, Q32854). Bacterial community composition in isolated DNA samples was characterized by amplification of the V4 variable region of the 16S rRNA gene by PCR using the barcoded primers 515 forward and 806 reverse following the Earth Microbiome Project protocol (http://www.earthmicrobiome.org/). Equimolar 16S rRNA PCR products from all samples were pooled prior to sequencing by the Duke Sequencing and Genomic Technologies shared resource on an Illumina MiSeq instrument configured for 250 base-pair paired-end sequencing runs. Raw sequence data can be found at the NIH Sequence Read Archive (submission in progress). Resulting data were processed using the Qiime2 bioinformatics platform (23). Data denoising was conducted with the DADA2 (24), Bioconductor (25) package in the R statistical programming environment. The RAxML algorithm (26) was used to generate the phylogenetic tree using a midpoint-rooting methodology. We used the Silva 132 classifier for taxonomic classification using variable region 4 (99% identity) (27).

Statistical analysis: Statistical analysis of taxonomic data, including relative abundance plots, alpha and beta diversity comparisons, and PCoA plots, were performed using the R packages Phyloseq v1.26.1, vegan 2.5.5 (28, 29), Phylogenetic Isometric Log-Ratio (PhILR) transformation (30), and LefSe (31). Relevant R code can be found at github (submission in progress).

RESULTS

We enrolled 294 adolescents (223 adolescents with obesity, or OB, and 71 healthy weight control adolescents, or HWC) (Table 1) between December, 2016 and July, 2019.

Approximately half (49.8% OB v. 54.9% HWC) of all participants identified as Black, while 19.3% of the OB group and 18.3% of the HWC group identified as Hispanic. Demographic characteristics of the interim analysis sample (27 OB and 27 HWC study participants) are shown in Table 2. Traditional laboratory parameters, including triglycerides, insulin, total cholesterol, blood pressure, and high- and low-density lipoprotein cholesterol (HDL and LDL, respectively) were analyzed and compared between the healthy weight cohort (HWC) and adolescents with obesity (OB) (All parameters collected are described in Supplemental Methods). Triglycerides, fasting glucose, LDL, and total cholesterol were not significantly different between HWC and OB after adusting for false discovery rates (FDR) (Table 2). We did find higher levels of homeostatic model of insulin resistance (HOMA-IR (32), HDL, glycated hemoglobin (Hb1Ac), C-reactive protein (CRP, Fig. 2), and alanine amino transferase (ALT, Fig. 2) in the OB as compared to the HWC control group, and lower levels of HDL cholesterol (Table 2).

Metabolic Profiling

After FDR adjustment for multiple comparisons, no metabolites were significantly different between the OB and HWC groups. However, several metabolites related to branched chain amino acid (BCAA) metabolism were nominally significantly different (Fig 3). Specifically, the BCAA valine (Fig. 3A) was higher in OB vs. HWC, while the ketoacid products of BCAA catabolism, α-ketoisocaproate (KIC) and α-keto-β-methylvalerate (KMV), were lower in OB vs HWC (Fig. 3B-C). Serum glycine (Fig. 3D) was also lower in OB when compared with HWC. We also observed higher serum glycerol and serum insulin in the OB vs. HWC group (Fig 3E-F).

Microbiome Profiling

Stool sample 16S rRNA gene sequence analysis revealed significant differences in measurements of alpha and beta diversity between OB and HWC groups (Fig. 4A, and Supplemental Fig. S1). However, we did not detect significant differences in alpha or beta diversity based on sex nor on age at sampling, suggesting that obesity as defined by %95th BMI was the main driver of the observed difference in microbiome diversity between groups (data not shown).

There were several bacterial taxa (here defined as a group of one or more populations of an organism or organisms that forms the lowest phylogenenetic unit identifiable by 16S rRNA gene sequencing) detected as differentially abundant in OB vs. HWC groups following analysis using the linear discriminant analysis (LDA) effect size tool (LEfSe) (Fig. 4C-D). Members of the Christensenellaceae and Ruminococcae UCG_14 families, along with an *Alistipes* species, were more likely to be found in samples from HWC, while two Lachnospiraceae families and a *Lachnospira* species were more likely to be associated with OB samples. To identify microbiome community configurations that might be associated with obesity, we examined the phylogenetic relatedness of microbes in each group using 2 different methods. In the first, we applied the Phylogenetic Isometric Log-Ratio (PhILR) transformation (Fig. 4D) to select taxonomic balances which were most effective at predicting patient membership in either the HWC or OB group. The abundance of *Eubacterium brachy* genera relative to the abundance of the Family XIII AD3011 group was higher in the HWC group as compared with OB. Conversely, the abundance ratio of Lachnospiraceae family members to *Ruminococcus gnavus* was substantially lower in the OB group as compared to HWC (Fig. 4D).

In the second phylogenetic analysis, species or lowest taxa relatedness was determined without regard to weight status (Fig. 5A). The resulting five phylogenetic clusters were then applied to weight status, revealing groups of related organisms that were then color coded and plotted. We found that some clusters were more likely to appear in the HWC cohort than the OB cohort, and vice versa (Fig. 5B). Taxa associated with the red cluster were more likely to be found in the OB group when compared with HWC, and this cluster appears to be driven by the decreased abundance of *Bacteroides* family members. Increased abundance of several Ruminococcae and specific members of the Provetellaceae was also more likely to be associated with OB (Fig. 5B and Supplemental Fig. S2).

DISCUSSION

In this interim analysis, we demonstrated proof of concept for 1) collection of clinical data, plasma and stool samples from a racially and ethnically diverse sample of adolescents with and without obesity, and 2) for conducting the analyses that may help to untangle the associations between microbiome and metabolome that contribute to health and disease. While representative of a small subset of the POMMS cohort, we observed interesting findings that both support and contradict existing adult data, and deserve further investigation.

Clinial lab measures are inconsistently effective at distinguishing obese vs. non-obese.

We did not detect significant differences in some laboratory screening measures for obesity co-morbidities between participants in the obese and non-obese cohorts. This is

not surprising, in part because of the small sample size, but also because larger studies have demonstrated that comorbidities in children present most clearly at the extremes of excess weight (33). Future analysis of the full POMMS cohort will be appropriately powered to confirm or refute this finding, however this early result suggests that some clinical labs may not be the most sensitive markers of early cardiovascular disease or diabetes. In contrast, levels of the inflammatory marker CRP and the liver function enzyme ALT were significantly higher in adolescents with obesity when compared to the healthy weight cohort. In a recent meta-analysis of pediatric weight loss trials, reduction in CRP and ALT scores were significantly correlated with BMI reduction over time (34). However, the fact that our interim OB participants are younger than the HWC due to pubertal stage at sampling (Table 2) should be considered when evaluating this data.

Targeted serum metabolite analysis confirms BCAA biomarkers of adult obesity are also present in adolescence, but demonstrates potential unique metabolic plasticity.

Analysis of targeted serum metabolite levels between HWC and OB groups revealed additional interesting results. We found that the branched-chain amino acid (BCAA) valine and the related branched chain ketoacids (BCKA) KMV and KIC were found at differing levels between OB and HWC cohorts, but only valine was positively associated with OB, while the BCKA were negatively associated with OB (Fig. 4). In addition, glycine levels were lower in our OB adolescents, consistent with studies in obese adults and rodent models (35) (Fig. 3D). These metabolites were analyzed in our adolescents as they are emerging biomarkers for obesity and future development of type 2 diabetes in adults (10). In fact, BCAA are typically elevated in adults with obesity and are among the strongest

baseline predictors of improvements in insulin sensitivity with weight loss (36) as well as later life development of type 2 diabetes in adults (10). However, unlike in adult obesity in humans and animals models, where BCAA and BCKA are both elevated, BCKA were lower in OB subjects from our adolescent cohort. This may be further evidence of an existing hypothesis that there is “metabolic plasticity” in youth protecting against insulin resistance by preventing mitochondrial overload of BCAA metabolites (10). Low plasma glycine levels may also be predictive of type 2 diabetes development, and plasma glycine levels increase with an improvement in insulin sensitivity (37).

Evidence suggests that levels of some metabolites such as circulating BCAA and fatty acid oxidation intermediates correlate with insulin resistance and higher HOMA-IR scores can be influenced by sex (38). To underscore this point, in a recent metabolomic survey of overweight and healthy weight children, BCAA and related metabolites trended as significantly different in obesity until the data was corrected for age, sex, and sexual maturity stage (39). However, in other larger studies, serum or plasma BCAA were significantly positively associated with obesity over a large age range of children and young adults (10). Indeed, in these larger studies with a combined sample size of over 1,000 HWC and OB children, the principal components with the largest contribution to risk factors of later cardiometabolic disease such as HOMA-IR and BMI were composed of the BCAA and their breakdown products. Thus, our data agree with these prior studies in that that elevated BCAA levels were associated with obesity in adolescents, and may provide rationale for more research into their viability as biomarkers of later life disease development (40). A recent attempt to identify such biomarkers of later life disease progression associated with obesity in 396 girls (mean age, 11.2 years at baseline) over a

7 year period demonstrated that serum levels of the BCAA leucine and isoleucine at baseline positively correlated with triglyceride levels at age 18, regardless of the triglyceride level at baseline (10).

Elevated glycerol levels in our OB cohort (Fig. 3E) suggest that adolescents with OB have increased levels of lipolysis. Lipolysis is elevated in adult obesity, resulting in higher circulating glycerol levels in adults, and in a recent study, partial inhibition of hormone sensitive lipase in mice and in human adipocytes led to improved insulin resistance and glucose uptake (41).

Adolescents with obesity may have specific microbiome characteristics based on 16S rRNA gene sequencing

We found significant differences in gut microbial community composition and presence or absence of specific taxa when comparing gut microbial 16S sequences between our HWC and OB interim cohort. While the majority of studies comparing gut microbes between OB and HWC have examined samples from adults, there are a few examples of studies that compare microbial consortia between obese and HWC children. A recent cross sectional study of 36 HWC and 42 Italian children with obesity aged 6-16 years (42) revealed that several individual microbes identified to their lowest taxonomic identifier correlated significantly either positively or negatively with an increasing BMI *z*-score (BMI normalized to age and sex), including *Bacteroides vulgatus* (R = -0.4321), *Faecalibacterium praustnitzii* (0.3508), and *Bacteroides stercoris* (-0.3252). A second study that examined differences between 81 HW, 29 overweight, and 80 OB children aged 9-11 years also found that *Faeacalibacterium* sp. was elevated with obesity, along with members of the Lachnospiraceae family (43), as we also demonstrated here. Further, our

study includes a racially and ethnically diverse group of adolescents, which we hope will help to add important insights that may eludicate the factors contributing to a higher prevalence of pediatric obesity in nonwhite populations (44). A recent analysis of microbiome data from obese subjects found that race and ethnicity are major drivers of microbiome diversity in humans, and low representiation of samples from diverse subjects might help explain varied outcomes when describing the microbiome phenotype in obesity (12).

One goal of our work is to identify microbes associated with healthy weight in youth that could be developed as probiotics to augment current standard of care. An early clinical trial with a single microbe to treat obesity in adults has promising results in that supplementation over 3 months appears safe and effective in reducing markers of inflammation and liver disfunction (45). These data suggest that microbial-based therapies are promising additions to the arsenal of current obesity treatments in adults, and our data will help extend probiotic trials to adolescent patients who may not respond to standard care.

We still lack evidence to connect the adolescent obese microbiome with metabolic changes associated with youth onset of obesity and the related metabolome. The data reported here on the interim set of participants was not sufficiently powered to make these connections, however we will have the ability to analyze microbial contributions to the metabolome in the samples extracted from our full POMMS cohort of nearly 300 individuals. Overall, our preliminary data suggest that adolescents with obesity inhabit a transitional space in which some indicators of health appear normal, while others may be strongly predicative of later life disease development. Future analyses of microbiota in

human and animal studies will help us define targets for new adolescent medicine therapeutics to intervene in what may otherwise be an unhealthy trajectory into adulthood.

CONCLUSION AND IMPACT

Early life obesity increases the lifetime risk for cardiovascular disease and other obesity-related diseases. The proposed research will directly address a critical gap in obesity treatment for children: how to deliver the recommended ≥26 hours of treatment in a 6-month period to diverse groups in a way that is effective and sustainable. Our interim analysis suggests that microbiome and metabolome resesearch in adolescent obesity mirrors some results in adult obesity, but also offers new targets for further research, specifically surrounding BCAA-related metabolism and investigating the role that specific microbial taxa have in association with obesity or healthy weight. This clinical-basic science collaboration has resulted in a diverse sample set that can be used to better understand metabolomic-microbiome profiles in the development of obesity.

Sources of Funding

National Institutes of Health R24-DK110492

American Heart Association 17SFRN33670990

Acknowledgements:

We would like to thank the study participants and their families for their involvement in this study. All raw data sequencing data will be made available via the NIH Sequence Read Archive (SRA) (submission in progress). Information on how to request access to the

clinical sample biorepository and deidentified participant data can be found at https://sites.duke.edu/pomms.

Disclosures

Svati H. Shah, Christopher B. Newgard: Unlicensed patent on a related finding.

Raphael H. Valdivia is a founder at Bloom Sciences, (San Diego, CA).

All other authors have declared no conflicts of interest.

REFERENCES

1. Pollock BD, Stuchlik P, Harville EW, Mills KT, Tang W, Chen W, et al. Life course trajectories of cardiovascular risk: Impact on atherosclerotic and metabolic indicators. Atherosclerosis. 2019;280:21-7.
2. Skinner AC, Ravanbakht SN, Skelton JA, Perrin EM, Armstrong SC. Prevalence of obesity and severe obesity in US children, 1999–2016. Pediatrics. 2018;141(3):e20173459.
3. Grossman DC, Bibbins-Domingo K, Curry SJ, Barry MJ, Davidson KW, Doubeni CA, et al. Screening for Obesity in Children and Adolescents: US Preventive Services Task Force Recommendation Statement. Jama. 2017;317(23):2417-26. Epub 2017/06/21. doi: 10.1001/jama.2017.6803. PubMed PMID: 28632874.
4. Ryder JR, Kaizer AM, Jenkins TM, Kelly AS, Inge TH, Shaibi GQ. Heterogeneity in Response to Treatment of Adolescents with Severe Obesity: The Need for Precision Obesity Medicine. Obesity. 2019;27(2):288-94. doi: 10.1002/oby.22369.
5. Cani PD, Hul MV, Lefort C, Depommier C, Rastelli M, Everard A. Microbial regulation of organismal energy homeostasis. Nature Metabolism. 2019;1(1):34-46. doi: 10.1038/s42255-018-0017-4.
6. Maruvada P, Leone V, Kaplan LM, Chang EB. The Human Microbiome and Obesity: Moving beyond Associations. Cell Host Microbe. 2017;22(5):589-99. Epub 2017/11/10. doi: 10.1016/j.chom.2017.10.005. PubMed PMID: 29120742.
7. Koh A, Backhed F. From Association to Causality: the Role of the Gut Microbiota and Its Functional Products on Host Metabolism. Mol Cell. 2020. Epub 2020/04/03. doi: 10.1016/j.molcel.2020.03.005. PubMed PMID: 32234490.
8. Freedman DS, Ogden CL, Kit BK. Interrelationships between BMI, skinfold thicknesses, percent body fat, and cardiovascular disease risk factors among U.S. children and adolescents. BMC Pediatr. 2015;15:188. Epub 2015/11/20. doi: 10.1186/s12887-015-0493-6. PubMed PMID: 26582570; PubMed Central PMCID: PMCPMC4652422.
9. Kuhle S, Tong O, Woolcott C. Association between caesarean section and childhood obesity: a systematic review and meta-analysis. Obesity Reviews. 2015;16(4):295-303.
10. Balikcioglu PG, Newgard CB. Metabolomic Signatures and Metabolic Complications in Childhood Obesity. In: Freemark M, editor. Pediatric Obesity: Etiology, Pathogenesis and Treatment: Springer; 2018.
11. Castaner O, Goday A, Park Y-M, Lee S-H, Magkos F, Shiow S-ATE, et al. The Gut Microbiome Profile in Obesity: A Systematic Review. Int J Endocrinol. 2018;2018. doi: 10.1155/2018/4095789.
12. Stanislawski MA, Dabelea D, Lange LA, Wagner BD, Lozupone CA. Gut microbiota phenotypes of obesity. npj Biofilms Microbiomes. 2019;5:18. Epub 2019/07/10. doi: 10.1038/s41522-019-0091-8. PubMed PMID: 31285833; PubMed Central PMCID: PMCPMC6603011.
13. Barlow SE. Expert committee recommendations regarding the prevention, assessment, and treatment of child and adolescent overweight and obesity: summary report. PEDIATRICS. 2007;120 Suppl 4:S164-92. Epub 2007/12/18. doi: 10.1542/peds.2007-2329C. PubMed PMID: 18055651.
14. Dolinsky DH, Armstrong SC, Walter EB, Kemper AR. The effectiveness of a primary care-based pediatric obesity program. Clinical pediatrics. 2012;51(4):345-53. Epub 2011/10/21. doi: 10.1177/0009922811425232. PubMed PMID: 22013148.
15. Flegal KM, Wei R, Ogden CL, Freedman DS, Johnson CL, Curtin LR. Characterizing extreme values of body mass index-for-age by using the 2000 Centers for Disease Control and Prevention growth charts. The American journal of clinical nutrition. 2009;90(5):1314-20. Epub 2009/09/25. doi: 10.3945/ajcn.2009.28335. PubMed PMID: 19776142.
16. LA. G. YMCA Fitness Testing and Assessment Manual, 4th ed. Human Kinetics. 2000;Champaign, IL.
17. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics. 2011;128 Suppl 5:S213-56. Epub 2011/11/16. doi: 10.1542/peds.2009-2107C. PubMed PMID: 22084329; PubMed Central PMCID: PMCPmc4536582.

18. Zeller MH, Modi AC. Development and initial validation of an obesity-specific quality-of-life measure for children: sizing me up. Obesity (Silver Spring). 2009;17(6):1171-7. Epub 2009/03/07. doi: 10.1038/oby.2009.47. PubMed PMID: 19265795; PubMed Central PMCID: PMCPMC3483635.
19. Tuck MK, Chan DW, Chia D, Godwin AK, Grizzle WE, Krueger KE, et al. Standard operating procedures for serum and plasma collection: early detection research network consensus statement standard operating procedure integration working group. J Proteome Res. 2009;8(1):113-7. Epub 2008/12/17. doi: 10.1021/pr800545q. PubMed PMID: 19072545; PubMed Central PMCID: PMCPMC2655764.
20. Ferrara CT, Wang P, Neto EC, Stevens RD, Bain JR, Wenner BR, et al. Genetic Networks of Liver Metabolism Revealed by Integration of Metabolic and Transcriptional Profiling. PLOS Genetics. 2008;4(3):e1000034. doi: 10.1371/journal.pgen.1000034.
21. Jensen MV, Joseph JW, Ilkayeva O, Burgess S, Lu D, Ronnebaum SM, et al. Compensatory Responses to Pyruvate Carboxylase Suppression in Islet β-Cells PRESERVATION OF GLUCOSE-STIMULATED INSULIN SECRETION. J Biol Chem. 2006;281(31):22342-51. doi: 10.1074/jbc.M604350200.
22. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. Journal of the Royal Statistical Society: Series B (Methodological). 1995;57(1):289-300. doi: 10.1111/j.2517-6161.1995.tb02031.x.
23. QIIME 2: Reproducible, interactive, scalable, and extensible microbiome data science. PeerJ. doi: 10.7287/peerj.preprints.27295v2
24. Callahan BJ, McMurdie PJ, Rosen MJ, Han AW, Johnson AJA, Holmes SP. DADA2: High-resolution sample inference from Illumina amplicon data. Nature Methods. 2016;13(7):581-3. doi: 10.1038/nmeth.3869.
25. Huber W, Carey VJ, Gentleman R, Anders S, Carlson M, Carvalho BS, et al. Orchestrating high-throughput genomic analysis with Bioconductor. Nature Methods. 2015;12(2):115-21. doi: 10.1038/nmeth.3252.
26. Stamatakis A. RAxML version 8: a tool for phylogenetic analysis and post-analysis of large phylogenies. Bioinformatics. 2014;30(9):1312-3. doi: 10.1093/bioinformatics/btu033.
27. Quast C, Pruesse E, Yilmaz P, Gerken J, Schweer T, Yarza P, et al. The SILVA ribosomal RNA gene database project: improved data processing and web-based tools. Nucleic Acids Res. 2013;41(D1):D590-D6. doi: 10.1093/nar/gks1219.
28. Oksanen J, Blanchet F, Kindt R, Legendre P, Minchin P, O'hara R, et al. Package 'vegan'. Community ecology package, version 2. 2013.
29. McMurdie PJ, Holmes S. phyloseq: an R package for reproducible interactive analysis and graphics of microbiome census data. PLOS ONE. 2013;8(4):e61217. Epub 2013/05/01. doi: 10.1371/journal.pone.0061217. PubMed PMID: 23630581; PubMed Central PMCID: PMCPMC3632530.
30. Silverman JD, Washburne AD, Mukherjee S, David LA. A phylogenetic transform enhances analysis of compositional microbiota data. Elife. 2017;6. Epub 2017/02/16. doi: 10.7554/eLife.21887. PubMed PMID: 28198697; PubMed Central PMCID: PMCPMC5328592.
31. Segata N, Huttenhower C. Toward an efficient method of identifying core genes for evolutionary and functional microbial phylogenies. PLOS ONE. 2011;6(9):e24704. Epub 2011/09/21. doi: 10.1371/journal.pone.0024704. PubMed PMID: 21931822; PubMed Central PMCID: PMCPMC3171473.
32. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412-9. Epub 1985/07/01. doi: 10.1007/bf00280883. PubMed PMID: 3899825.
33. Skinner AC, Perrin EM, Moss LA, Skelton JA. Cardiometabolic Risks and Severity of Obesity in Children and Young Adults. New England Journal of Medicine. 2015;373(14):1307-17. doi: 10.1056/NEJMoa1502821.
34. Matson RI, Perry R, Hunt LP, Chong AH, Beynon R, Hamilton-Shield J, et al. Change in obesity-related metabolic abnormalities associated with body mass index improvement through life-style intervention: A meta-regression. Pediatr Diabetes. 2020;21(2):173-93. Epub 2019/12/11. doi: 10.1111/pedi.12955. PubMed PMID: 31820534.
35. White PJ, Lapworth AL, An J, Wang L, McGarrah RW, Stevens RD, et al. Branched-chain amino acid restriction in Zucker-fatty rats improves muscle insulin sensitivity by enhancing efficiency of fatty acid oxidation

and acyl-glycine export. Mol Metab. 2016;5(7):538-51. Epub 2016/07/14. doi: 10.1016/j.molmet.2016.04.006. PubMed PMID: 27408778; PubMed Central PMCID: PMCPMC4921791.

36. Shah SH, Crosslin DR, Haynes CS, Nelson S, Turer CB, Stevens RD, et al. Branched-chain amino acid levels are associated with improvement in insulin resistance with weight loss. Diabetologia. 2012;55(2):321-30. Epub 2011/11/09. doi: 10.1007/s00125-011-2356-5. PubMed PMID: 22065088; PubMed Central PMCID: PMCPMC3667157.

37. Adeva-Andany M, Souto-Adeva G, Ameneiros-Rodriguez E, Fernandez-Fernandez C, Donapetry-Garcia C, Dominguez-Montero A. Insulin resistance and glycine metabolism in humans. Amino Acids. 2018;50(1):11-27. Epub 2017/11/03. doi: 10.1007/s00726-017-2508-0. PubMed PMID: 29094215.

38. Newbern D, Gumus Balikcioglu P, Balikcioglu M, Bain J, Muehlbauer M, Stevens R, et al. Sex Differences in Biomarkers Associated With Insulin Resistance in Obese Adolescents: Metabolomic Profiling and Principal Components Analysis. J Clin Endocrinol Metab. 2014;99(12):4730-9. doi: 10.1210/jc.2014-2080.

39. Michaliszyn SF, Sjaarda LA, Mihalik SJ, Lee S, Bacha F, Chace DH, et al. Metabolomic Profiling of Amino Acids and β-Cell Function Relative to Insulin Sensitivity in Youth. The Journal of Clinical Endocrinology & Metabolism. 2012;97(11):E2119-E24. doi: 10.1210/jc.2012-2170.

40. Rangel-Huerta OD, Pastor-Villaescusa B, Gil A. Are we close to defining a metabolomic signature of human obesity? A systematic review of metabolomics studies. Metabolomics. 2019;15(6):93. Epub 2019/06/15. doi: 10.1007/s11306-019-1553-y. PubMed PMID: 31197497; PubMed Central PMCID: PMCPMC6565659.

41. Girousse A, Tavernier G, Valle C, Moro C, Mejhert N, Dinel A-L, et al. Partial Inhibition of Adipose Tissue Lipolysis Improves Glucose Metabolism and Insulin Sensitivity Without Alteration of Fat Mass. PLoS Biol. 2013;11(2):e1001485. doi: 10.1371/journal.pbio.1001485.

42. Riva A, Borgo F, Lassandro C, Verduci E, Morace G, Borghi E, et al. Pediatric obesity is associated with an altered gut microbiota and discordant shifts in Firmicutes populations. Environ Microbiol. 2017;19(1):95-105. doi: 10.1111/1462-2920.13463.

43. Murugesan S, Ulloa-Martínez M, Martínez-Rojano H, Galván-Rodríguez FM, Miranda-Brito C, Romano MC, et al. Study of the diversity and short-chain fatty acids production by the bacterial community in overweight and obese Mexican children. Eur J Clin Microbiol Infect Dis. 2015;34(7):1337-46. doi: 10.1007/s10096-015-2355-4.

44. Stovitz SD, Schwimmer JB, Martinez H, Story MT. Pediatric obesity: the unique issues in Latino-American male youth. American journal of preventive medicine. 2008;34(2):153-60. Epub 2008/01/19. doi: 10.1016/j.amepre.2007.09.034. PubMed PMID: 18201646.

45. Depommier C, Everard A, Druart C, Plovier H, Hul MV, Vieira-Silva S, et al. Supplementation with *Akkermansia muciniphila* in overweight and obese human volunteers: a proof-of-concept exploratory study. Nature Medicine. 2019;25(7):1096. doi: 10.1038/s41591-019-0495-2.

TABLES

Table 1. Description of all study participants in the Healthy Weight Control (HWC) and Adolescents with Obesity (OB) cohort.

Characteristics	HWC	OB
Participants	71	223
Sex (F/M/NA)	38/32/1	132/88/0
Intervention:		
Lifestyle		164
Low Carb		14
Pharmaceuticals		36
Surgery		6
Race:		
Black	39 (54.9%)	111 (49.8%)
White	26 (36.6%)	88 (39.5%
Black/White	2 (2.8%)	13 (5.8%)
Other	2 (2.8%)	8 (3.6%)
Missing Data	2 (2.8%)	0
Ethnicity:		
Hispanic	13 (18.3%)	43 (19.3%)
Non-Hispanic	57 (80.3%)	177 (79.4%)
Other	1 (1.4%)	0
Average %95th BMI	75 ± 7	134 ± 32
Average age at entry	15 ± 1.8	13.5 ± 2.3
Average Tanner stage	3.9 ± 1.1	3.5 ± 1.2

Percentages of total are included in parentheses for numbers describing Race and Ethnicity. Numbers represent actual number of participants or mean result ± standard deviation.

ScholarOne, 375 Greenbrier Drive, Charlottesville, VA, 22901

Table 2. Demographics and clinical lab results for study participants included in the interim analysis.

	HWC	**OB**	FDR adj. p-value
Participants	27	27	
Sex (F/M)	15/12	15/12	
Intervention:			
Lifestyle		21	
Low Carb		3	
Pharmaceuticals		2	
Surgery		1	
Race:			
Black	13	12	
White	12	11	
Black/White	0	2	
Other	2	2	
Average p95 BMI	75.6 ± 5.	137.8 ± 48.7	
Average Age at Entry	15.0± 1.7	12.6 ± 2.4	
Clinical Labs:			
Triglycerides (mg/dl)	84.7 ± 35.6	113.7 ± 75.2	0.14
HDL (mg/dl)	54.1 ± 14.1	45.6 ± 11.1	0.02*
LDL (mg/dl)	84.9 ± 30.5	100.1 ± 25.3	0.06
Glucose (mg/dl)	84.6 ± 9.9	88.9± 9.1	0.12
HOMA-IR	2.4 ± 2.8	4.0 ± 3.1	0.01*
HbA1c (IU/dl)	5.2 ± 0.3	5.4 ± 0.4	0.01*
Cholesterol (mg/dl)	155.9 ± 38.7	163.9 ± 29.0	0.41

Numbers respresent actual number of participants or mean result ± standard deviation. HDL, high density lipoprotein; LDL, low density lipoprotein; HbA1c, percent acylated (glycated) hemoglobin; HOMA-IR, homeostatic model of insulin resistance.

ScholarOne, 375 Greenbrier Drive, Charlottesville, VA, 22901

FIGURE LEGENDS

Figure 1. POMMS study design. Adolescents between 10 and 18 with either BMI >5th %ile to < 85th percentile (healthy weight controls, or HWC) or BMI equal to or over the 95th percentile (adolescents with obesity, or OB) were recruited to join the study. Target numbers of recruits for each intervention are indicated, along with actual recruitment numbers. Age matched HWC recruits had clinical measurements of health as well as serum, stool, and PBMCs collected at a single timepoint, while OB recruits were evaluated and offered a treatment arm that was clinically relevant depending on the individual. OB recruits then had clinical measurements of health, blood, PBMC and stool samples taken at baseline, 3 months, and 6 months (or termination) of the study. Stool samples were also collected from OB patients at 1.5 and 4.5 months after the first visit. All samples are stored in replicates in the POMMS Biorepository managed within the Duke Children's Biobank to be made available for research purposes.

Figure 2. **Clinical lab measurements of liver function and inflammation were significantly higher in OB v HWC**. Log transformed serum values of alanine transferase (ALT) and C-reactive protein (CRP) were compared at baseline between healthy weight control (HWC) and adolescents with obesity (OB). Error bars indicate standard deviation of the mean. *** = P< 0.001 following correction for multiple testing. See Methods for details on statistical analysis.

Figure 3. **Serum metabolites associated with obesity in adults were significantly different in our adolescent interim cohort at baseline**. Log transformed serum metabolite values are presented. Error bars indicate standard deviation of the mean. *, p<0.05. **, p<0.01. See Methods for details on statistical analysis.

ScholarOne, 375 Greenbrier Drive, Charlottesville, VA, 22901

Figure 4. **A subset of adolescents with obesity have reduced gut microbial diversity and differences in abundance of specific microbial taxa when compared to their healthy weight counterparts**. **(A)** Shannon α-diversity and Bray Curtis β-diversity metrics between HWC and OB stool 16S rRNA gene sequences based on identified amplicon sequence variants. (**B-C**) The Linear discriminant analysis (LDA) effect size tool (LEfSe) was applied to taxonomic data resulting from 16S rRNA gene amplicon sequencing. (**B**) Relative abundance of taxa with that vary significantly by cohort are displayed. (**C**) Count data of each taxon with a significantly different abundance between HWC and OB cohorts in the LDA analysis. Each symbol represents abundance in an individual sample. **(D**) PhiLR Taxa identified by 16S rRNA gene sequencing that were present at a read count of > 3 across at least 10% of patient samples were retained for analysis. PhiLR results are displayed as log relative abundances of opposing clades in a phylogenetic tree and significant balances were chosen on the basis of a simple predictive model. A PhILR value greater than zero indicates greater abundance of the numerator component relative to the denominator component and a negative value indicates the reverse. These balances were most effective at predicting patient membership in either the HWC or OB cohort. See Methods section for details on statistical analyses and access to relevant R code.

Figure 5: **Phylogenetic clustering of gut microbial taxa suggest that genetic relationships predict presence or absence of taxa in OB cohorts**. **(A)** Taxa identified by 16S rRNA gene amplicon sequencing were subjected to unsupervised clustering into 5 taxonomic clusters and grouped by color and treatment status. Each terminal node of the tree represents results from an individual fecal sample. **(B)** Clusters were assigned a color and

ScholarOne, 375 Greenbrier Drive, Charlottesville, VA, 22901

each fecal sample result was grouped by cluster in (A) and then divided by HWC or OB status in order of participant ID number. See methods for links to relevant R code and raw data.

ScholarOne, 375 Greenbrier Drive, Charlottesville, VA, 22901



Figure 1. POMMS study design. Adolescents between 10 and 18 with either BMI >5th %ile to < 85th percentile (healthy weight controls, or HWC) or BMI equal to or over the 95th percentile (adolescents with obesity, or OB) were recruited to join the study. Target numbers of recruits for each intervention are indicated, along with actual recruitment numbers. Age matched HWC recruits had clinical measurements of health as well as serum, stool, and PBMCs collected at a single timepoint, while OB recruits were evaluated and offered a treatment arm that was clinically relevant depending on the individual. OB recruits then had clinical measurements of health, blood, PBMC and stool samples taken at baseline, 3 months, and 6 months (or termination) of the study. Stool samples were also collected from OB patients at 1.5 and 4.5 months after the first visit. All samples are stored in replicates in the POMMS Biorepository managed within the Duke Children's Biobank to be made available for research purposes.

279x215mm (300 x 300 DPI)



Figure 2. Clinical lab measurements of liver function and inflammation were significantly higher in OB v HWC. Log transformed serum values of alanine transferase (ALT) and C-reactive protein (CRP) were compared at baseline between healthy weight control (HWC) and adolescents with obesity (OB). Error bars indicate standard deviation of the mean. *** = P< 0.001 following correction for multiple testing. See Methods for details on statistical analysis.

195x73mm (300 x 300 DPI)

FIGURE 3



Figure 3. Serum metabolites associated with obesity in adults were significantly different in our adolescent interim cohort at baseline. Log transformed serum metabolite values are presented. Error bars indicate standard deviation of the mean. *, $p<0.05$. **, $p<0.01$. See Methods for details on statistical analysis.

154x179mm (300 x 300 DPI)

FIGURE 4



Figure 4. A subset of adolescents with obesity have reduced gut microbial diversity and differences in abundance of specific microbial taxa when compared to their healthy weight counterparts. (A) Shannon □-diversity and Bray Curtis □-diversity metrics between HWC and OB stool 16S rRNA gene sequences based on identified amplicon sequence variants. (B-C) The Linear discriminant analysis (LDA) effect size tool (LEfSe) was applied to taxonomic data resulting from 16S rRNA gene amplicon sequencing. (B) Relative abundance of taxa with that vary significantly by cohort are displayed. (C) Count data of each taxon with a significantly different abundance between HWC and OB cohorts in the LDA analysis. Each symbol represents abundance in an individual sample. (D) PhiLR Taxa identified by 16S rRNA gene sequencing that were present at a read count of > 3 across at least 10% of patient samples were retained for analysis. PhiLR results are displayed as log relative abundances of opposing clades in a phylogenetic tree and significant balances were chosen on the basis of a simple predictive model. A PhILR value greater than zero indicates greater abundance of the numerator component relative to the denominator component and a negative value indicates the reverse. These balances were most effective at predicting patient membership in either the HWC or OB cohort. See Methods section for details on statistical analyses and access to relevant R code.

312x227mm (300 x 300 DPI)

FIGURE 5



Figure 5: Phylogenetic clustering of gut microbial taxa suggest that genetic relationships predict presence or absence of taxa in OB cohorts. (A) Taxa identified by 16S rRNA gene amplicon sequencing were subjected to unsupervised clustering into 5 taxonomic clusters and grouped by color and treatment status. Each terminal node of the tree represents results from an individual fecal sample. (B) Clusters were assigned a color and each fecal sample result was grouped by cluster in (A) and then divided by HWC or OB status in order of participant ID number. See methods for links to relevant R code and raw data.

313x215mm (300 x 300 DPI)

The Pediatric Obesity Microbiome and Metabolism Study (POMMS): Methods, Baseline Data, and Early Insights.

Supplemental Material

Authors and Affiliations:

Jessica R. McCann, PhD[1] (jessica.mccann@duke.edu)

Nathan A. Bihlmeyer, PhD[2] (nathan.bihlmeyer@duke.edu)

Kimberly Roche[1] (kimberly.roche@duke.edu)

Cameron Catherine[3] (cameroncatherine3@gmail.com)

Jayanth Jawahar[1] (jayanth.jawahar@duke.edu)

Lydia Coulter Kwee, PhD[2] (lydia.kwee@duke.edu)

Noelle E. Younge, MD[3] (noelle.younge@duke.edu)

Justin Silverman (jsilve24@gmail.com)

Olga Ilkayeva, PhD[2] (olga.ilkayeva@duke.edu)

Charles Sarria[1] (charlesjsarria@ufl.edu)

Alexandra Zizzi[1] (alexandra.zizzi@duke.edu)

Janet Wootton[1] (janet.wootton@duke.edu)

Lisa Poppe[2] (lisa.poppe@duke.edu)

Paul Anderson[2] (paul.r.anderson@duke.edu)

Michelle Arlotto[2] (michellee.arlotto@duke.edu)

Zhengzheng Wei, PhD[1] (zhengzheng.wei@duke.edu)

Joshua A. Granek, PhD[1,5] (joshua.granek@duke.edu)

Raphael H. Valdivia, PhD[1,5] (raphael.valdivia@duke.edu

Lawrence A. David, PhD[1,5] (lawrence.david@duke.edu)

Holly K. Dressman, PhD[1,5] (holly.dressman@duke.edu)

Christopher B. Newgard, PhD[2] (chris.newgard@duke.edu)

Svati H. Shah, MD MHS[2,4] (svati.shah@duke.edu)

Patrick C. Seed, MD PhD[6] * (patrick.seed@northwestern.edu)

John F. Rawls, PhD[1,5] * (john.rawls@duke.edu)

Sarah C. Armstrong, MD[3,4] * (sarah.c.armstrong@duke.edu)

1. Department of Molecular Genetics and Microbiology, Duke University, Durham, NC 27708
2. Duke Molecular Physiology Institute and Sarah W. Stedman Nutrition and Metabolism Center, Duke University, Durham, NC, USA 27710
3. Department of Pediatrics, Duke University, Durham, NC, USA 27710
4. Duke Clinical Research Institute, Duke University, Durham, NC, USA 27710
5. Duke Microbiome Center, Duke University Durham, NC, USA 27710
6. Ann & Robert H. Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine, Stanley Manne Children's Research Institute, Northwestern University Medical Center, Chicago, IL, USA 60611

Supplemental Methods:

Community Based Fitness Program, or "Bull City Fit"

The program offers opportunities for families to participate in sports and games, cooking classes, gardening, and swimming for up to two hours per day, six days per week. This intervention, when paired with the clinical program, demonstrates better engagement, increased physical activity, reductions in HDL cholesterol, decreases in waist circumference, and improved quality of life.[1,2] The community program has demonstrated engagement among a racially-diverse population, with attendance ranging from 10-105 hours of participation over 6 months. In addition, high levels of participation are associated with significant BMI z-score reduction at 6 months (-0.03 among those participating 20 hours or less versus -0.1 among those participating 80 hours or more, p=0.02),[1,3] and improvement in physical activity and quality of life as compared with usual care.[4] More details describing the program implementation can be found at https://www.bullcityfit.org .

Challenges with enrollment and follow up and potential solutions

One of the challenges with enrollment in this study was the fact that participants were recruited from a specialty clinic, limiting the number of potential participants based on the smaller nature of the clinic. Various socioeconomic factors such as transportation or ability to take time off work affects patient's ability to attend clinic visits and thus limits our enrollment to some extent. In order to mitigate the effect of these barriers to clinic, providers and clinical research coordinators connect patients with financial care counselors and scheduling coordinators to find personalized solutions for each family.

The baseline blood draw was most easily obtained due to the fact that prospective participants were already fasting and in clinic for their appointment. The follow up blood draws were more challenging due to the dependence of the participants on a guardian to bring them to clinic. Clinical research coordinators attempted to work around the participant's school schedule

as well as the work schedule of their guardian in order to obtain the blood sample within the correct time frame. The variability in the schedules of the participants presented a different challenge: matching up the timing of the blood and stool samples. Our goal was to obtain the blood sample within a week of obtaining the stool sample; however, this was not always feasible due to the nature of working with human participants. One way to mitigate this type of variability was to instruct the participant to collect their stool sample the night before coming in for their follow up blood draw.

Another challenge that we encountered was maintaining active participants over the full 6-month study period. To reduce the number of participants lost to follow up, clinical research coordinators maintained communication with participants via text or phone call before and after samples were collected so that participants knew the timing of their study related responsibilities. Coordinators also discussed the incentives offered throughout the study and timeline of when these incentives would be given to the participants.

Strategies for increased adherence were guided by advocacy committees comprised of Healthy Lifestyles patients and their families not currently involved in the study. The advocacy committee provided advice on how to best retain participants. Researchers also generated a monthly newsletter that described different study goals and the plans for the data collected. Newsletters were delivered to participants homes as motivational tools to encourage study completion.

Supplemental Table 1

Measures and Schedule of Assessments						
Measure	Description	0m	1.5 m	3m	4.5 m	6m
Child and Family Characteristics						
Demographics	Race and ethnicity, medical record number, date of birth, zip code, distance from clinic, gender at birth, parent primary language, child's primary insurance, annual household income, parent's text-enabled mobile number	x				
Child nutrition questionnaire		x	x	x	x	x
Observational Group Identifier	Lifestyle only, low CHO diet, metformin, topiramate, phentermine, weight loss surgery, vyvanse, healthy weight sibling, healthy weight non-sibling	x		x		x
New visit characteristics-child	Past medical history (asthma, ADHD, developmental delay, past GI surgery), child birth weight and gestational age, antibiotics history during first year of life, medication list, food allergies, number of pets in household	x				
New visit characteristics-parent	Birth delivery method, breast feeding history, mom/dad diabetes history					
Return visit-child	Date of visit, review of systems: headaches, snoring, acanthosis grade, medications: probiotics, antibiotic use in past 1 month		x	x	x	x
PHQ-9 Modified for Teens		x				x
Food insecurity screen		x				
Primary Outcome						
Child BMI	Directly measured height and weight using calibrated Tanita (Tanita, TBF 300, Arlington Heights, Ill).	x	x	x	x	x
Child body fat percent	Measured via bioelectrical impedance (Tanita, TBF 300, Arlington Heights, Ill).	x		x		x
Child basal metabolic rate	Measured via bioelectrical impedance (Tanita, TBF 300, Arlington Heights, Ill).	x		x		x
Child Waist Circumference (cm)	Standardized waist circumference measured by trained personnel, using cloth measuring tape, at level of umbilicus	x				x
Secondary Outcomes						

Child fitness	Baseline, 3-min, and 4-in heart rate after submaximal (3-min) bench-stepping test (YMCA)	x		x		x
Fit Score	Measured by Healthy Lifestyles Physical Therapists	x		x		x
Child blood pressure	Measured with calibrated auscultatory sphygmomanometer, supine position, appropriately sized cuff.[70]	x	x	x	x	x
Fasting lipid profile	Obtained as per standard protocol in Healthy Lifestyles clinic	x				x
Fasting glucose	Obtained as per standard protocol in Healthy Lifestyles clinic	x				x
Fasting insulin	Obtained as per standard protocol in Healthy Lifestyles clinic	x				x
Alanine aminotransferase	Obtained as per standard protocol in Healthy Lifestyles clinic	x				x
C reactive protein	Obtained as per standard protocol in Healthy Lifestyles clinic	x				x
Glycated hemoglobin	Obtained as per standard protocol in Healthy Lifestyles clinic	x				x
Caregiver identifier	Identifier of which biological/non-biological parent whose BMI was measured	x		x		x
Parent BMI	Directly measured height and weight using calibrated Tanita (Tanita, TBF 300, Arlington Heights, Ill).	x				
Basic Science Measures						
Research Blood	Fasting serum samples	x		x		x
Stool microbiome	16S rRNA gene sequencing on all and metagenomics on matched 0 and 6mo sample sets	x	x	x	x	x

Supplemental Figures:



Figure S1. Non-metric multidimensional scaling (NMDS) plot of Bray-Curtis dissimilarity in fecal samples from healthy weight control (HWC) or adolescents with obesity (OB). Ellipses represent 95% confidence around each group. Stress, a measure of how well the NMDS procedure was able to represent high dimensional data in lower dimensional space, is shown along with whether or not the procedure converged (TRUE). Data was preprocessed using the phyloseq R package to prune rare taxa (fewer than 3 reads in 10% of samples) and low-abundance samples (fewer than 50 total reads), as well as for plotting, and the vegan R package was used for ordination.



Figure S2. Relative abundance of all Family-level taxa organized by health status. HWC, Healthy Weight Control; OB, adolescents with obesity. Raw counts were converted to relative abundance and transformed into percentages using the transform_sample_counts function in the phyloseq R package. No taxa were pruned prior to plotting.

Metabolite	Number	Beta	SE	Tval	Pval	adj.Pval
GLYC	52	2.44	0.81	3.00	0.003	0.08
Insulin	52	2.67	0.90	2.96	0.003	0.08
Gly	52	-11.46	3.60	-3.18	0.001	0.08
Ser	52	-13.81	4.90	-2.82	0.005	0.09
KIC	52	-5.85	2.29	-2.55	0.011	0.13
KMV	52	-5.42	2.11	-2.57	0.010	0.13
Tyr	52	7.25	3.01	2.41	0.016	0.17
C5-DC	52	-3.26	1.39	-2.34	0.019	0.18
Val	52	6.67	2.96	2.25	0.024	0.20
NEFA	52	0.94	0.56	1.69	0.091	0.40
GLU	52	5.52	3.34	1.65	0.098	0.40
TRIG	50	1.25	0.67	1.86	0.062	0.40
URIC	52	2.97	1.58	1.88	0.060	0.40
Phe	52	4.18	2.56	1.63	0.103	0.40
Asx	52	-2.27	1.35	-1.68	0.093	0.40
Cit	52	-3.37	1.98	-1.71	0.088	0.40
C6	36	3.33	1.96	1.70	0.090	0.40
C6-DC/C8-OH	52	-1.48	0.83	-1.78	0.075	0.40
C12-OH/C10-DC	51	-1.43	0.82	-1.75	0.081	0.40
Met	52	-4.56	2.91	-1.56	0.118	0.43
C8:1-DC	52	-1.72	1.11	-1.55	0.122	0.43
C4-DC/Ci4-DC	52	-1.37	0.90	-1.52	0.128	0.43
Arg	52	3.11	2.25	1.38	0.166	0.49
C8:1-OH/C6:1-DC	52	-1.21	0.87	-1.39	0.164	0.49
C16:1	52	1.00	0.74	1.35	0.176	0.49
C18	52	-1.34	0.99	-1.35	0.178	0.49
C20	50	-1.18	0.88	-1.35	0.177	0.49
Glx	52	2.58	1.99	1.30	0.194	0.51
Orn	52	-1.82	1.43	-1.28	0.201	0.51
C3	52	1.67	1.35	1.24	0.217	0.52
C20-OH/C18-DC	51	-1.37	1.11	-1.23	0.218	0.52
C16-OH/C14-DC	51	0.98	0.82	1.20	0.230	0.53
C12:1	52	0.71	0.60	1.18	0.238	0.53
KET	52	0.45	0.39	1.15	0.251	0.55
Leu/Ile	52	2.92	2.62	1.11	0.265	0.56
C18:1-DC	52	-0.92	0.84	-1.10	0.271	0.56
C7-DC	18	3.32	3.12	1.07	0.287	0.57
C18:2-OH	49	-1.08	1.06	-1.02	0.308	0.58
3-HIB	52	0.98	0.96	1.03	0.303	0.58
C10:3	52	-1.02	1.03	-0.99	0.320	0.59
C10-OH/C8-DC	52	-0.63	0.69	-0.91	0.362	0.65
LACT	52	-1.25	1.42	-0.88	0.379	0.65
His	52	-2.41	2.85	-0.85	0.398	0.65
C4-OH	52	0.46	0.53	0.88	0.380	0.65
C10	51	-0.54	0.63	-0.85	0.394	0.65
Ala	52	1.16	1.56	0.75	0.456	0.73
C5:1	52	-1.05	1.62	-0.65	0.518	0.78
C5	52	-0.59	0.89	-0.66	0.512	0.78
C16:1-OH/C14:1-DC	52	-0.53	0.80	-0.66	0.508	0.78

C2	52	0.63	1.01	0.62	0.533	0.79
HBUT	52	0.15	0.33	0.45	0.655	0.84
C8:1	52	-0.38	0.82	-0.46	0.643	0.84
C10:1	52	0.33	0.62	0.53	0.599	0.84
C14:2	52	0.22	0.49	0.45	0.656	0.84
C14:1-OH	52	-0.40	0.89	-0.45	0.655	0.84
C14-OH/C12-DC	52	-0.39	0.86	-0.45	0.649	0.84
C16:2	52	0.29	0.60	0.50	0.620	0.84
C18-OH/C16-DC	51	-0.43	0.94	-0.46	0.647	0.84
C5-OH/C3-DC	51	-0.35	0.89	-0.39	0.699	0.86
C18:2	52	-0.37	0.94	-0.39	0.696	0.86
C18:1-OH/C16:1-DC	52	-0.32	0.92	-0.35	0.730	0.89
Pro	52	-0.57	1.74	-0.33	0.742	0.89
BUN	52	-0.26	1.23	-0.21	0.835	0.89
C8	52	0.10	0.52	0.19	0.846	0.89
C10:2	52	0.27	1.04	0.26	0.796	0.89
C12	52	-0.11	0.61	-0.18	0.854	0.89
C14:1	52	0.12	0.51	0.24	0.813	0.89
C14	52	0.21	0.84	0.25	0.800	0.89
C16	52	-0.21	1.11	-0.19	0.851	0.89
C18:1	52	-0.21	0.80	-0.26	0.797	0.89
C22	52	0.20	0.87	0.23	0.816	0.89
KIV	52	0.20	1.92	0.11	0.916	0.94
C20:4	52	-0.02	0.86	-0.03	0.979	0.99
C4/Ci4	52	0.01	1.10	0.01	0.994	0.99

STROBE Statement—Checklist of items that should be included in reports of ***case-control studies***

	Item No	Recommendation	Page No
Title and abstract	1	(*a*) Indicate the study's design with a commonly used term in the title or the abstract	1
		(*b*) Provide in the abstract an informative and balanced summary of what was done and what was found	4
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	5, 6
Objectives	3	State specific objectives, including any prespecified hypotheses	4, 7
Methods			
Study design	4	Present key elements of study design early in the paper	8
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	7
Participants	6	(*a*) Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls	7
		(*b*) For matched studies, give matching criteria and the number of controls per case	N/A
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	Supplement
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	9, 10
Bias	9	Describe any efforts to address potential sources of bias	Supplement
Study size	10	Explain how the study size was arrived at	7, 11
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	9-12
Statistical methods	12	(*a*) Describe all statistical methods, including those used to control for confounding	11
		(*b*) Describe any methods used to examine subgroups and interactions	11
		(*c*) Explain how missing data were addressed	N/A (see pg 11)
		(*d*) If applicable, explain how matching of cases and controls was addressed	N/A
		(*e*) Describe any sensitivity analyses	N/A
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	12
		(b) Give reasons for non-participation at each stage	Supplement
		(c) Consider use of a flow diagram	Fig 1
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	13
		(b) Indicate number of participants with missing data for each variable of	25

ScholarOne, 375 Greenbrier Drive, Charlottesville, VA, 22901

		interest	
Outcome data	15*	Report numbers in each exposure category, or summary measures of exposure	13, 14

ScholarOne, 375 Greenbrier Drive, Charlottesville, VA, 22901

Main results	16	(*a*) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	?
		(*b*) Report category boundaries when continuous variables were categorized	
		(*c*) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	
Discussion			
Key results	18	Summarise key results with reference to study objectives	15
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	19
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	19, 20
Generalisability	21	Discuss the generalisability (external validity) of the study results	
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	20

*Give information separately for cases and controls.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at http://www.strobe-statement.org.

ScholarOne, 375 Greenbrier Drive, Charlottesville, VA, 22901